COMMUNIQUÉS West-GlobeNewswire

EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases
14/10/2025
Press Release EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, [...]
Dewpoint Therapeutics Announces Presentation at AACR-NCI-EORTC 2025
14/10/2025
Dewpoint will present one poster at AACR-NCI-EORTC MYC is a highly desirable oncogenic target that historically eluded drug hunters Small molecules that inhibit the oncogenic function of MYC were discovered using [...]
HIV Self-Testing Just Got Faster: FDA Approves the 1-Minute INSTI® HIV Self Test
14/10/2025
The fastest, at-home HIV test is now available in the U.S., expanding access to rapid, private, and convenient self-testing A Major Step Forward in HIV Prevention The INSTI ® HIV Self Test delivers highly accurate [...]
Bicycle Health Grows Leadership Team to Further Expand Access to Opioid Use Disorder Care for Patients in the Criminal Justice System
14/10/2025
Steve Tomlin has decades of experience bringing opioid and substance use disorder care to criminal justice populations BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Bicycle Health , the nation’s largest provider of virtual [...]
Rendever Leads Expansion of Virtual Reality in Hospice Care
14/10/2025
The AgeTech company expands hospice partnerships to enhance end-of-life care with immersive experiences for patients and families BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Rendever , the company leading the industry in [...]
BPGbio Welcomes Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in Residence
14/10/2025
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision Oncology Initiatives BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc [...]
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
14/10/2025
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single- [...]
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
14/10/2025
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
14/10/2025
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the [...]
Assembly Biosciences Announces Upcoming Investor Conference Participation
14/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that [...]
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
14/10/2025
SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
Iantrek Announces Commercial Launch of AlloFlo™ Uveo, the Only Surgical Treatment Targeting the Uveoscleral Pathway in Glaucoma
14/10/2025
AlloFlo™ Uveo expands interventional options for glaucoma surgeons and patients With over 100 surgeon partners and thousands of cases performed throughout the early-release program, Iantrek pioneers a new era in [...]
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
14/10/2025
Purespring Therapeutics to Present at Chardan’s 9 th Annual Genetic Medicines Conference London – 14 October 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney [...]
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
14/10/2025
Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a [...]
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
14/10/2025
― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a [...]
Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines Conference
14/10/2025
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced [...]
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
14/10/2025
CHATHAM, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a pipeline of [...]
Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
14/10/2025
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase [...]
Frontier Medicines Announces Third Precision Oncology Development Candidate
14/10/2025
- FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, targeting the largest genetic drivers of cancer - - Potential as a monotherapy and as a [...]

Pages